# EDGAR Filing Document

**Accession Number:** 0001769804
**File Stem:** 0001213900-23-002492
**Filing Date:** 2023-1
**Character Count:** 11229
**Document Hash:** e75857d1220b59c4c4f71bd01ff94d52
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-002492.hdr.sgml**: 20230112

**ACCESSION NUMBER**: 0001213900-23-002492

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230109

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230112

**DATE AS OF CHANGE**: 20230112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Augmedix, Inc.
- **CENTRAL INDEX KEY:** 0001769804
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-BUSINESS SERVICES, NEC [7389]
- **IRS NUMBER:** 833299164
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40890
- **FILM NUMBER:** 23525960

**BUSINESS ADDRESS:**
- **STREET 1:** 111 SUTTER STREET, SUITE 1300
- **CITY:** SAN FRANCISC
- **STATE:** CA
- **ZIP:** 94104
- **BUSINESS PHONE:** 561-989-2208

**MAIL ADDRESS:**
- **STREET 1:** 111 SUTTER STREET, SUITE 1300
- **CITY:** SAN FRANCISC
- **STATE:** CA
- **ZIP:** 94104

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Malo Holdings Corp
- **DATE OF NAME CHANGE:** 20190305

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): January 9, 2023**

**AUGMEDIX, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40890** | **83-3299164** |
| **(State or other jurisdiction**<br>**of incorporation)**  | **(Commission** **File Number)**  | **(I.R.S. Employer**<br>**Identification No.)**<br>|

---

**111 Sutter Street, Suite 1300, San Francisco, California 94104**

**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code: (888) 669-4885**

**N/A**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value per share | AUGX | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01. Entry into a Material Definitive Agreement**

On January 9, 2023 (the "***Effective Date***"), Augmedix Operating Corp., a Delaware corporation (the "***Company***"), and subsidiary of Augmedix, Inc., entered into Statement of Work No. 3 ("***SOW No.3***") with Sutter Health ("***Sutter***"), pursuant to the Master Services Agreement (the "***MSA***"), dated April 15, 2015, by and between the Company and Sutter. Pursuant to SOW No.3, the Company will provide two (2) electronic health records coordinators (a primary and backup) for Sutter, for a term commencing on the Effective Date and expiring on April 14, 2024, unless terminated earlier as provided in the MSA or SOW No.3.

A copy of SOW No.3 is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The foregoing description of SOW No.3 does not purport to be complete and is qualified in its entirety by reference to the full text of SOW No.3.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 10.1\* | [Statement of Work No.3, dated January 9, 2023, by and between Augmedix Operating Corp. and Sutter Health.](ea171608ex10-1_augmedix.htm) |
| 104 | Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document. |

---

\* Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the SEC.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **AUGMEDIX, INC.** | **AUGMEDIX, INC.** |
| Dated: January 12, 2023 | By: | /s/ Paul Ginocchio |
|  |  | Paul Ginocchio |
|  |  | Chief Financial Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [\*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

**STATEMENT OF WORK NO. 3 FOR [\*\*\*] STAFF AUGMENTATION**

**SUTTER BAY MEDICAL FOUNDATION**

This Statement of Work (the "**SOW**") is pursuant to and governed by the terms of Master Services Agreement entered into on April 15, 2015 (the "**Agreement**"), between **SUTTER HEALTH** ("**Customer**" or "**Sutter**") and **AUGMEDIX OPERATING CORP. F/K/A AUGMEDIX, INC.** ("**Supplier**" or "**Augmedix**") and shall become effective (the "**Effective Date**") upon the date signed by both Parties.

&nbsp;&nbsp;&nbsp;&nbsp;I. Introduction/Background

Supplier shall provide the following [\*\*\*] staff augmentation for Sutter:

● Two (2) EHR Coordinators (primary and backup)

Services are contingent upon offshore staffing through Supplier's Bangladesh operations.

 ****

&nbsp;&nbsp;&nbsp;&nbsp;II. Scope of Work

The following is an overview of role / Supplier scribe onboarding duties:

The EHR Coordinator role is responsible for supporting cross-functional processes across Sutter Health and Augmedix to onboard and provision electronic health record (EHR) credentials for Medical Documentation Specialists ("MDS")/Scribes serving Sutter providers. The goal is to streamline and drive continuous process improvement in Supplier MDS onboarding and Epic EHR provisioning and to support Supplier services across Sutter to ensure the Supplier/Customer partnership and scaling efforts meet or exceed 2023 (and the following year(s)) growth targets.

The EHR Coordinator will drive EHR and compliance management administration and process improvement in support of Customer. Interaction with Supplier internal, cross-functional teams and Customer team members will enable a streamlined process for onboarding Supplier MDSs supporting Customer providers. The EHR Coordinator works in conjunction with cross-discipline teams (e.g., Customer Success, Information Technology (IT), Operations) to execute all tasks related to onboarding an MDS, provisioning Epic EHR credentials, and reporting on a fixed cadence to all appropriate Supplier and Customer project stakeholders.

Responsibilities (including but not limited to):

● Assigning Customer permissions/credentials that allow the EHR Coordinator to complete the following tasks in onboarding / credentialing an Epic username/log-in for MDS/scribes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Supplier
 Scribe Onboarding via Online Access Request (OAR); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;o Supplier
 Scribe Onboarding via Identity and Access Management (IAM) system - copy/paste permissioning.

● Building and maintaining working relationships with Augmedix team members, Customer project contacts, and other departments involved in the projects.

● Keeping projects on schedule while coordinating with Supplier MDS/service providers and project staff, and engage leadership as necessary.

● Setting deadlines, assigning responsibilities, and monitoring/tracking EHR requests and compliance policies.

● Managing multiple specialty and locations onboardings at once

● Participating in team meetings cross functionally and succinctly summarizing progress of projects or pending EHR requests.

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [\*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO AUGMEDIX, INC. IF PUBLICLY DISCLOSED.

● Managing issue logs, resolution, status and risk to enable project success.

● Customer ticket creation, escalation, and ticket closing according to proper workflows.

● Creating and maintaining written and web-based training aides.

● Training and supporting the development of "super users" in each functional area and region requiring utilization and access to the Customer Epic instance, including by conducting webinar sessions for training both existing and new Supplier service providers on the Customer Epic instance as needed to drive continuous process improvements.

&nbsp;&nbsp;&nbsp;&nbsp;III. Period
 of Per formance

The term of this SOW shall commence upon the Effective Date and shall expire on April 14, 2024 ("SOW Term"), unless terminated earlier as provided in the Agreement or herein.

&nbsp;&nbsp;&nbsp;&nbsp;IV. Termination

Either Party may terminate this SOW upon 90-days prior written notice to the other Party

&nbsp;&nbsp;&nbsp;&nbsp;V. Place of Performance

This SOW shall be performed remotely.

 ****

&nbsp;&nbsp;&nbsp;&nbsp;VI. Schedule/Milestones

Supplier shall complete all work stated herein by April 14, 2024.

 ****

&nbsp;&nbsp;&nbsp;&nbsp;VII. Other Requirements

Customer shall provide Customer support full access to Epic, Customer Network, Customer Email, OAR system, IAM system, Customer secure site (SecureShare).

&nbsp;&nbsp;&nbsp;&nbsp;VIII. PRICE/FEES

[\*\*\*] staff augmentation support for Sutter.

No other Supplier costs or fees shall be permitted without Customer's written authorization. Changes to SOW shall be through written authorization as agreed upon by parties through a Change Order process.

---

| | | | |
|:---|:---|:---|:---|
| **SUTTER HEALTH:** | **SUTTER HEALTH:** | **AUGMEDIX OPERATING CORP. F/K/A AUGMEDIX, INC.:** | **AUGMEDIX OPERATING CORP. F/K/A AUGMEDIX, INC.:** |
| By: | /s/ Jennifer Carlson | By: | /s/ Manny Krakaris |
| Name: | Jennifer Carlson | Name: | Manny Krakaris |
| Title: | Sr. Director, Supply Chain Services | Title: | CEO |
| Date: | 1/9/2023 | Date: | 1/4/2023 |

---